Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation”

1 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 1 of 1 results

Early research (Phase 1)Study completedNCT02259114
What this trial is testing

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Who this might be right for
NUT Midline CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation+3 more
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 47